Date: 2015-01-12
Type of information: Termination of the agreement
Compound: alisporivir (DEB025)
Company: Novartis (Switzerland) Debiopharm (Switzerland)
Therapeutic area: Infectious diseases
Type agreement:
Action mechanism: This oligopeptide is a cyclophilin (Cyp)-binding molecule with potent anti-hepatitis C virus (HCV) activity both in vitro and in vivo. It binds to CypA, a peptidyl-prolyl cis-transisomerase which is a crucial cofactor for HCV replication.
Disease: hepatitis C
Details: * On January 12, 2015, Debiopharm, a Swiss-based global biopharmaceutical company, announced that it has updated its arrangement with Novartis to regain full rights to Alisporivir (DEB025) currently completing two Phase 2 studies of interferon-free treatment in Hepatitis C. \"Novartis has decided that, as part of an ongoing portfolio transformation, hepatitis C virus (HCV)-related indications would no longer be a strategic focus for them\" said Thierry Mauvernay, Delegate of the Board of Debiopharm Group. Debiopharm is now looking forward to continuing the development of this exciting molecule in one or more indications and the company has already started discussing with potential partners. Debiopharm and Novartis entered into a strategic collaboration for the development of Alisporivir in January 2010. This arrangement allows for the transfer, at Debiopharm\'s election, of ongoing Alisporivir Phase 2 clinical trials to Debiopharm and transfers all rights for HCV and other indications.
Financial terms:
Latest news:
